{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:59:01Z","timestamp":1793350741185,"version":"4.5.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA260508"],"award-info":[{"award-number":["U01CA260508"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>SARS-CoV-2 variants continue to circulate globally, even within highly vaccinated populations. The first-generation SARS-CoV-2 vaccines elicit neutralizing immunoglobin G (IgG) antibodies that prevent severe COVID-19 but induce only weak antibody responses in mucosal tissues. There is increasing recognition that secretory immunoglobin A (SIgA) antibodies in the upper respiratory tract and oral cavity are critical in interrupting virus shedding, transmission, and progression of disease. To fully understand the immune-related factors that influence SARS-CoV-2 dynamics at the population level, it will be necessary to monitor virus-specific IgG and SIgA in systemic and mucosal compartments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>Oral fluids and saliva, with appropriate standardized collection methods, constitute a readily accessible biospecimen type from which both systemic and mucosal antibodies can be measured. Serum-derived IgG and immunoglobin A (IgA) are found in gingival crevicular fluids and saliva as the result of transudation, while SIgA, which is produced in response to mucosal infection and vaccination, is actively transported across salivary gland epithelia and present in saliva and passive drool. In this mini-review, we summarize the need for the implementation of standards, highly qualified reagents, and best practices to ensure that clinical science is both rigorous and comparable across laboratories and institutions. We discuss the need for a better understanding of sample stability, collection methods, and other factors that affect measurement outcomes and interlaboratory variability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The establishment of best practices and clinical laboratory standards for the assessment of SARS-CoV-2 serum and mucosal antibodies in oral fluids is integral to understanding immune-related factors that influence COVID-19 transmission and persistence within populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvad169","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T20:30:21Z","timestamp":1701462621000},"page":"589-596","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Assessment of SARS-CoV-2 Antibodies in Oral Fluids Following Infection and Vaccination"],"prefix":"10.1093","volume":"70","author":[{"given":"Christopher D","family":"Heaney","sequence":"first","affiliation":[{"name":"Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD , United States"},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD , United States"},{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Hempel","sequence":"additional","affiliation":[{"name":"Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research , Frederick, MD , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-2667","authenticated-orcid":false,"given":"Kate L","family":"DeRosa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, NewYork State Department of Health, Wadsworth Center , Albany, NY , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia A","family":"Pinto","sequence":"additional","affiliation":[{"name":"Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research , Frederick, MD , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-8640","authenticated-orcid":false,"given":"Nicholas J","family":"Mantis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, NewYork State Department of Health, Wadsworth Center , Albany, NY , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2024040223561366000_hvad169-B1","doi-asserted-by":"crossref","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"2024040223561366000_hvad169-B2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"2024040223561366000_hvad169-B3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.annonc.2021.12.006","article-title":"COVID-19 vaccination and breakthrough infections in patients with cancer","volume":"33","author":"Schmidt","year":"2022","journal-title":"Ann Oncol"},{"key":"2024040223561366000_hvad169-B4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-023-00654-6","article-title":"Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report","volume":"8","author":"Knisely","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2024040223561366000_hvad169-B5","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S1473-3099(23)00421-8","article-title":"Mucosal IgA protects against BQ.1 and BQ.1.1 infection","volume":"23","author":"Marking","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024040223561366000_hvad169-B6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/path.5679","article-title":"Salivary glands are a target for SARS-CoV-2: a source for saliva contamination","volume":"254","author":"Matuck","year":"2021","journal-title":"J Pathol"},{"key":"2024040223561366000_hvad169-B7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.20411\/pai.v6i1.441","article-title":"Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in Saliva","volume":"6","author":"Ketas","year":"2021","journal-title":"Pathog Immun"},{"key":"2024040223561366000_hvad169-B8","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1038\/s41598-022-12869-z","article-title":"Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity","volume":"12","author":"Thomas","year":"2022","journal-title":"Sci Rep"},{"key":"2024040223561366000_hvad169-B9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1196\/annals.1384.012","article-title":"Do salivary antibodies reliably reflect both mucosal and systemic immunity?","volume":"1098","author":"Brandtzaeg","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2024040223561366000_hvad169-B10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.xphs.2019.07.018","article-title":"Preformulation characterization and stability assessments of secretory IgA monoclonal antibodies as potential candidates for passive immunization by oral administration","volume":"109","author":"Hu","year":"2020","journal-title":"J Pharm Sci"},{"key":"2024040223561366000_hvad169-B11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nm0598-601","article-title":"Characterization of a recombinant plant monoclonal secretory antibody and preventative immunotherapy in humans","volume":"4","author":"Ma","year":"1998","journal-title":"Nat Med"},{"key":"2024040223561366000_hvad169-B12","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1016\/S2666-5247(23)00102-7","article-title":"Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose","volume":"4","author":"Bladh","year":"2023","journal-title":"Lancet Microbe"},{"key":"2024040223561366000_hvad169-B13","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMc2209651","article-title":"Anti-Spike mucosal IgA protection against SARS-CoV-2 omicron infection","volume":"387","author":"Havervall","year":"2022","journal-title":"N Engl J Med"},{"key":"2024040223561366000_hvad169-B14","doi-asserted-by":"crossref","first-page":"e20220638","DOI":"10.1084\/jem.20220638","article-title":"Potent human broadly SARS-CoV-2\u2013neutralizing IgA and IgG antibodies effective against omicron BA.1 and BA.2","volume":"219","author":"Planchais","year":"2022","journal-title":"J Exp Med"},{"key":"2024040223561366000_hvad169-B15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","author":"Sheikh-Mohamed","year":"2022","journal-title":"Mucosal Immunol"},{"key":"2024040223561366000_hvad169-B16","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S1473-3099(21)00472-2","article-title":"Prevention of host-to-host transmission by SARS-CoV-2 vaccines","volume":"22","author":"Mostaghimi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024040223561366000_hvad169-B17","author":"Mallory"},{"key":"2024040223561366000_hvad169-B18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(23)00001-4","article-title":"Tracking immune correlates of protection for emerging SARS-CoV-2 variants","volume":"23","author":"Nilles","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024040223561366000_hvad169-B19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/imr.13118","article-title":"Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS-CoV-2 infection","volume":"309","author":"Sheikh-Mohamed","year":"2022","journal-title":"Immunol Rev"},{"key":"2024040223561366000_hvad169-B20","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1016\/S2666-5247(23)00135-0","article-title":"The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens and host immunity","volume":"4","author":"Laxton","year":"2023","journal-title":"Lancet Microbe"},{"key":"2024040223561366000_hvad169-B21","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2018.03.034","article-title":"Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel(R) sponges","volume":"36","author":"Parker","year":"2018","journal-title":"Vaccine"},{"key":"2024040223561366000_hvad169-B22","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1016\/j.vaccine.2019.03.064","article-title":"HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged men","volume":"37","author":"Parker","year":"2019","journal-title":"Vaccine"},{"key":"2024040223561366000_hvad169-B23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"2024040223561366000_hvad169-B24","doi-asserted-by":"crossref","first-page":"20401","DOI":"10.3402\/jom.v5i0.20401","article-title":"Secretory immunity with special reference to the oral cavity","volume":"5","author":"Brandtzaeg","year":"2013","journal-title":"J Oral Microbiol"},{"key":"2024040223561366000_hvad169-B25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/infdis\/jiw359","article-title":"Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial","volume":"214","author":"Pinto","year":"2016","journal-title":"J Infect Dis"},{"key":"2024040223561366000_hvad169-B26","doi-asserted-by":"crossref","first-page":"831744","DOI":"10.3389\/fcimb.2022.831744","article-title":"Long-term post-COVID-19 associated oral inflammatory sequelae","volume":"12","author":"Alfaifi","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2024040223561366000_hvad169-B27","doi-asserted-by":"crossref","first-page":"e02204-20","DOI":"10.1128\/JCM.02204-20","article-title":"COVID-19 Serology at population scale: SARS-CoV-2-specific antibody responses in Saliva","volume":"59","author":"Pisanic","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2024040223561366000_hvad169-B28","doi-asserted-by":"crossref","article-title":"Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19","author":"Varadhachary","DOI":"10.1101\/2020.08.07.20170258"},{"key":"2024040223561366000_hvad169-B29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/infdis\/jiab256","article-title":"Persisting salivary IgG against SARS-CoV-2 at 9 months after mild COVID-19: A complementary approach to population surveys","volume":"224","author":"Alkharaan","year":"2021","journal-title":"J Infect Dis"},{"key":"2024040223561366000_hvad169-B30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/mab.2016.0014","article-title":"Novel monoclonal antibodies for studies of human and rhesus macaque secretory component and human J-chain","volume":"35","author":"Zhang","year":"2016","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"2024040223561366000_hvad169-B31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12916-021-02184-1","article-title":"Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain","volume":"19","author":"Doba\u00f1o","year":"2021","journal-title":"BMC Med"},{"key":"2024040223561366000_hvad169-B32","doi-asserted-by":"crossref","first-page":"618685","DOI":"10.3389\/fimmu.2020.618685","article-title":"Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals","volume":"11","author":"Butler","year":"2020","journal-title":"Front Immunol"},{"key":"2024040223561366000_hvad169-B33","doi-asserted-by":"crossref","article-title":"Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infection","author":"Nahass","DOI":"10.1101\/2021.08.22.21262168"},{"key":"2024040223561366000_hvad169-B34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4049\/jimmunol.2100919","article-title":"The kinetics of COVID-19 vaccine response in a community-vaccinated population","volume":"208","author":"Tu","year":"2022","journal-title":"J Immunol"},{"key":"2024040223561366000_hvad169-B35","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.4049\/jimmunol.2100934","article-title":"Development and validation of an enzyme immunoassay for detection and quantification of SARS-CoV-2 salivary IgA and IgG","volume":"208","author":"Costantini","year":"2022","journal-title":"J Immunol"},{"key":"2024040223561366000_hvad169-B36","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3390\/jcm9051491","article-title":"Use of Saliva for diagnosis and monitoring the SARS-CoV-2: A general perspective","volume":"9","author":"Ceron","year":"2020","journal-title":"J Clin Med"},{"key":"2024040223561366000_hvad169-B37","first-page":"134","article-title":"Immunity and exposure to hepatitis A virus in pre-adolescent children from a multi-ethnic inner city area","volume":"7","author":"Morris-Cunnington","year":"2004","journal-title":"Commun Dis Public Health"},{"key":"2024040223561366000_hvad169-B38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-030-35784-9_3","volume-title":"Salivary bioscience: foundations of interdisciplinary Saliva research and applications","author":"Padilla","year":"2020"},{"key":"2024040223561366000_hvad169-B39","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.1038\/s41598-022-10484-6","article-title":"Quantitative serology for SARS-CoV-2 using self-collected saliva and finger-stick blood","volume":"12","author":"Campbell","year":"2022","journal-title":"Sci Rep"},{"key":"2024040223561366000_hvad169-B40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10654-007-9105-6","article-title":"A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium","volume":"22","author":"Quoilin","year":"2007","journal-title":"Eur J Epidemiol"},{"key":"2024040223561366000_hvad169-B41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/BMI.S607","article-title":"Sample stability and protein composition of Saliva: implications for its use as a diagnostic fluid","volume":"3","author":"Esser","year":"2008","journal-title":"Biomark Insights"},{"key":"2024040223561366000_hvad169-B42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-1759(02)00114-X","article-title":"Stability of total and rubella-specific IgG in oral fluid samples: the effect of time and temperature","volume":"266","author":"Morris","year":"2002","journal-title":"J Immunol Methods"},{"key":"2024040223561366000_hvad169-B43","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMc2016359","article-title":"Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2","volume":"383","author":"Wyllie","year":"2020","journal-title":"N Engl J Med"},{"key":"2024040223561366000_hvad169-B44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0194599820982633","article-title":"COVID-19 Vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission","volume":"164","author":"Bleier","year":"2021","journal-title":"Otolaryngol Head Neck Surg"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/70\/4\/589\/57140751\/hvad169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/70\/4\/589\/57140751\/hvad169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T23:56:43Z","timestamp":1712102203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/70\/4\/589\/7457423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2024,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvad169","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,12,1]]}}}